Engineered Calcitonin Fragment Binds Both Bone and Diabetes Receptors With 21x Improved Affinity
Three mutations in salmon calcitonin fragment sCT(22-32) increased calcitonin receptor binding 21-fold while retaining high affinity for all three amylin receptor subtypes — a potential lead for dual osteoporosis/diabetes therapy.
Quick Facts
What This Study Found
Three mutations (N26D, S29P, P32HYP) in sCT(22-32) increased CTR ECD affinity 21-fold. The mutated fragment also retained high affinity for all 3 AMY receptor ECD types (CTR:RAMP1, CTR:RAMP2, CTR:RAMP3).
Key Numbers
21-fold affinity increase; mutations N26D, S29P, P32HYP; retained binding to AMY1, AMY2, AMY3 receptor ECDs
How They Did This
Peptide biochemistry study. Purified CTR and AMY receptor extracellular domains (ECDs). Fluorescence polarization/anisotropy peptide binding assays. Systematic mutation screening of sCT(22-32) fragment.
Why This Research Matters
Osteoporosis and diabetes often co-occur in aging. A single peptide fragment that engages both calcitonin (bone) and amylin (metabolic) receptors could simplify treatment for elderly patients with both conditions.
The Bigger Picture
Calcitonin and amylin share receptor components, and this study exploits that relationship to design a multi-target peptide. The approach of engineering short receptor-binding fragments could be applied to other GPCR families for multi-indication drugs.
What This Study Doesn't Tell Us
In vitro binding study using isolated receptor domains — full receptor activation and in vivo efficacy not tested. Short fragment may not fully activate receptors. Pharmacokinetics of the 11-mer peptide unknown. Clinical translation requires substantial development.
Questions This Raises
- ?Does the mutated sCT(22-32) fragment activate CTR and AMY receptors functionally, not just bind?
- ?Could this fragment be lipidated or PEGylated for extended half-life?
- ?Would dual CTR/AMY activation provide synergistic benefits for metabolic bone disease?
Trust & Context
- Key Stat:
- 21x stronger binding Just three amino acid changes boosted calcitonin receptor binding 21-fold while maintaining affinity for all three amylin receptor subtypes — a dual-targeting short peptide lead
- Evidence Grade:
- Low evidence grade: in vitro receptor binding study with isolated ECDs. Functional activation and in vivo effects not demonstrated.
- Study Age:
- Published 2021. Next-generation calcitonin and amylin receptor drugs continue in development.
- Original Title:
- Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors.
- Published In:
- Biomolecules, 11(9) (2021)
- Authors:
- Lee, Sangmin(4)
- Database ID:
- RPEP-05536
Evidence Hierarchy
Frequently Asked Questions
Why target both calcitonin and amylin receptors?
Calcitonin receptors control bone metabolism (important for osteoporosis), while amylin receptors help regulate blood sugar and appetite (important for diabetes). Since these receptors share components, a single short peptide could potentially treat both conditions — common in aging populations.
How can just 3 mutations improve binding 21-fold?
Each mutation was strategically chosen to improve how the peptide fits into the receptor's binding pocket. N26D and S29P optimized charge interactions, while P32HYP (hydroxyproline) improved structural rigidity. Together, these small changes dramatically strengthened binding.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05536APA
Lee, Sangmin. (2021). Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors.. Biomolecules, 11(9). https://doi.org/10.3390/biom11091364
MLA
Lee, Sangmin. "Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors.." Biomolecules, 2021. https://doi.org/10.3390/biom11091364
RethinkPeptides
RethinkPeptides Research Database. "Development of High Affinity Calcitonin Analog Fragments Tar..." RPEP-05536. Retrieved from https://rethinkpeptides.com/research/lee-2021-development-of-high-affinity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.